SCHEMBL1848429

SCHEMBL1848429

O=C(O)c1cc(-c2ccc(OCCCOC3CCCCO3)cc2)c(-c2ccc(F)cc2Cl)s1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.38
PRKAB2 O43741 10/20 0.37
PRKAG1 P54619 10/20 0.37
PRKAA2 P54646 10/20 0.37
PRKAA1 Q13131 10/20 0.37
PRKAG3 Q9UGI9 10/20 0.37
PRKAG2 Q9UGJ0 10/20 0.37
PRKAB1 Q9Y478 10/20 0.37
MAPK14 Q16539 1/20 0.37
FFAR4 Q5NUL3 3/20 0.35
FFAR1 O14842 2/20 0.35
ESR1 P03372 2/20 0.35
ESR2 Q92731 1/20 0.35
NOTUM Q6P988 1/20 0.34
CYP2C9 P11712 1/20 0.34
SCN5A Q14524 1/20 0.34
RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2158549 0.93 MEN1 (0.44) MEN1KMT2AL3MBTL1PRKAB2PRKAG1
SCHEMBL1850707 0.89 MEN1 (0.53) MEN1KMT2APRKAB2PRKAG1PRKAA2
SCHEMBL1850456 0.83 MEN1 (0.38) MEN1KMT2AMAPK14
SCHEMBL1850453 0.83 MEN1 (0.38) MEN1KMT2A
SCHEMBL2158729 0.82 MEN1 (0.46) MEN1KMT2AL3MBTL1FFAR4FFAR1
SCHEMBL2158953 0.82 CNR1 (0.38) MEN1KMT2AL3MBTL1PRKAB2PRKAG1
SCHEMBL1848319 0.81 PRKAB2 (0.50) PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3
SCHEMBL1846961 0.81 OPRL1 (0.37) MEN1KMT2AMAPK14
SCHEMBL1846958 0.81 MEN1 (0.36) MEN1KMT2ACYP2C9
SCHEMBL1849014 0.80 MEN1 (0.35) MEN1KMT2APRKAB2PRKAG1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2324015-B1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2013-07-03 EP disclosed
US-8410137-B2 Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-04-02 US disclosed
US-20110183960-A1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-28 US disclosed
EP-2324015-A2 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF Sanofi-aventis (FR) 2011-05-25 EP disclosed
WO-2010012964-A2 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2010-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183960-A1 THIOPHENE-2-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF NR3C2, NR1H3, NR1H2 MEN1 4467/4885KMT2A 2317/4885L3MBTL1 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.